Communication intervention
OtherParticipate in PLAN intervention
NCT Number: NCT04889144
This trial tests whether Planning for Your Advance Care Needs (PLAN) intervention works to enhance Latino patients' understanding of and engagement in advanced care planning. The PLAN intervention may be an effective method to help people with cancer plan for and talk about advance care planning (the care they would want if they were unable to communicate) with their loved ones and doctors.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Weill Cornell Medicine, New York, United States
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients participate in PLAN intervention, consisting of 3 coaching sessions over 45-60 minutes each with a health coach.
ARM II: Patients receive usual care.
After completion of study treatment, patients are followed up at 1 week and then at 3 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participate in PLAN intervention
Receive usual care
Other names: standard of care, standard therapy
Ancillary studies
Time frame: Five weeks post-randomization (for intervention arm only)
Will be measured by intervention completion (Benchmark: >= 70% complete the intervention sessions).
Time frame: Five weeks post-randomization (for intervention arm only)
Will be measured by a single-item question assessing helpfulness of the intervention (1 = not at all helpful, 5 = very helpful) as well an open-ended question about helpfulness of the intervention ("What was helpful about the intervention?") (Benchmark: >= 70% rate it as "helpful" or "very helpful"). Data reported as a count number of those who reported "4=helpful" or "5=very helpful" to this question.
Time frame: Baseline, five weeks post-randomization (after randomizing and completing the 3-week intervention if assigned)
Knowledge subscale of the Advance Care Planning Engagement survey, which is a 49-item scale with high reliability (Cronbach's alpha = .94). Subscale is 6 items with Likert-type answers ranging from 1=not at all to 5=extremely. Responses to these 6 items are summed to create total scores, ranging from 6 (low levels of knowledge) to 30 (high levels of knowledge). Higher scores indicate higher levels of knowledge. Mean score differences were calculated between baseline and follow-up for each study arm and tested for significance.
Time frame: Baseline, five weeks post-randomization (after randomizing and completing the 3-week intervention if assigned)
Readiness/motivation subscale of the Advance Care Planning Engagement survey, which is a 49-item scale with high reliability (Cronbach's alpha = .94). Subscale is 10 items with Likert-type answers ranging from 1=not at all to 5=extremely. Scores from these items are summed to created total scores, ranging from 10 (low level of readiness/motivation) to 60 (high level of readiness/motivation). Higher scores indicate higher levels of readiness/motivation. Mean score differences were calculated between baseline and follow-up for each study arm and tested for significance.
Time frame: Baseline, five weeks post-randomization (after randomizing and completing the 3-week intervention if assigned)
Self-efficacy subscale of the Advance Care Planning Engagement survey, which is a 49-item scale with high reliability (Cronbach's alpha = .94). Subscale is 6 items with Likert-type answers ranging from 1=not at all to 5=extremely. These items are summed to create total scores, ranging from 6 (low levels of self-efficacy) to 30 (high levels of self-efficacy). Higher scores indicated higher levels of self-efficacy. Mean score differences were calculated between baseline and follow-up for each study arm and tested for significance.
Data reported is the mean change in this outcome from pre-randomization/baseline to post-randomization.
Time frame: Baseline, five weeks post-randomization (after randomizing and completing the 3-week intervention if assigned)
End-of-life care discussions will be measured by asking patients to self-report whether they have discussed any of the following: (1) wishes they have about the care they would like to receive if they were dying and/or (2) advance care directives, with an oncology provider or family member: DNR orders, living wills, durable powers of attorney for health care (yes/no format). Engagement will be measured as a count to the degree to which they engaged in each of these, with no=0 and yes=1. Total score can range from 0 (low or none) to 8 (high or discussed all domains with providers and family). Data reported is the mean change in this outcome from pre-randomization/baseline to post-randomization,
Time frame: Baseline, five weeks post-randomization (after randomizing and completing the 3-week intervention if assigned)
Completion of advance directives will be assessed by examining the medical chart for completed advance directive documents (DNR order, living will, health care proxy/durable power of attorney). Completion will be measured as a count to the degree to which they completed each of these, with no=0 and yes=1. Scores can range from 0 (low or none completed) to 3 (high or all completed). Data reported is the mean change in this outcome from pre-randomization/baseline to post-randomization.
Fred Hutchinson Cancer Center
Other
Latinos' Beliefs and Communication About Advance Care Planning
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05564468
Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm
Seattle, Washington, United States
View Trial DetailsNCT01902173
Hematologic Diseases, Hematologic Neoplasms
Los Angeles, California, United States
View Trial DetailsNCT05058339
Advanced Malignant Solid Neoplasm, COVID-19
Houston, Texas, United States
View Trial DetailsNCT02595866
AIDS-Related Non-Hodgkin Lymphoma, Adenocarcinoma
Birmingham, Alabama, United States
View Trial Details